Dan Levine has advised clients in strategic and financial transactions, principally involving China, for nearly 20 years. He focuses his practice on inbound and outbound M&A, joint ventures, private equity and venture capital investments, and technology licensing transactions.

Dan provides strategic and transactional advice to Chinese and Western clients navigating geopolitical, legal, and regulatory hurdles to their global strategies—including national security reviews conducted by the Committee on Foreign Investment in the United States (CFIUS), China’s outbound investment review process, the U.S.’s proposed outbound investment screening regime, China’s overseas listing rules, and export controls.

Dan has extensive experience in the clean energy, life sciences, and technology sectors. In recent years he has:

advised a leading global electric vehicle battery and energy storage companies with respect to incentive programs under the Bipartisan Infrastructure Law and Inflation Reduction Act;
advised a leading global medical device company in a joint venture with a Chinese state-owned entity to develop and commercialize imaging equipment in China; and
advised JW Therapeutics, a China-based cell therapy company, in a complex asset acquisition and in-licensing transaction with Eureka Therapeutics.

Dan’s pro bono work includes representing U.S. health care professionals and Chinese companies to procure and supply personal protective equipment from China to the United States during the COVID-19 pandemic.

Dan was based in Covington’s Shanghai office from 2013-2022 and reads, writes, and speaks Mandarin.